Neoadjuvant pembrolizumab-based therapy versus dual HER2 blockade in early breast cancer: comparable surgical complication rates in a real-world cohort.
- DOI
- 10.3389/fmed.2026.1917346
- Published
- 2026
- Container
- Frontiers in medicine
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.3389/fmed.2026.1917346,
title = {Neoadjuvant pembrolizumab-based therapy versus dual HER2 blockade in early breast cancer: comparable surgical complication rates in a real-world cohort.},
author = {Wimmer K and Kantner K and Exner R and Bartsch R and Bago-Horvath Z and Konrad S and Fitzal F and Marhold M},
year = {2026},
journal = {Frontiers in medicine},
doi = {10.3389/fmed.2026.1917346},
url = {https://doi.org/10.3389/fmed.2026.1917346}
}RIS
TY - JOUR TI - Neoadjuvant pembrolizumab-based therapy versus dual HER2 blockade in early breast cancer: comparable surgical complication rates in a real-world cohort. AU - Wimmer K AU - Kantner K AU - Exner R AU - Bartsch R AU - Bago-Horvath Z AU - Konrad S AU - Fitzal F AU - Marhold M PY - 2026 JO - Frontiers in medicine DO - 10.3389/fmed.2026.1917346 UR - https://doi.org/10.3389/fmed.2026.1917346 ER -
APA
K, W., K, K., R, E., R, B., Z, B., S, K., F, F., & M, M. (2026). Neoadjuvant pembrolizumab-based therapy versus dual HER2 blockade in early breast cancer: comparable surgical complication rates in a real-world cohort.. Frontiers in medicine. https://doi.org/10.3389/fmed.2026.1917346
Source records
- pubmed · retrieved 2026-09-25T06:52:45.604Z